disease with corneal neovascularization MedDRA version: 12.0 Level: LLT Classification code 10055665 Term: Corneal neovascularisation
Conditions
Interventions
Trade Name: AVASTIN
Pharmaceutical Form: Solution for infusion
INN or Proposed INN: Bevacizumab
Concentration unit: µg microgram(s)
Concentration type: equal
Concentration number: 5-
Sponsors
POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: eye disease with severe corneal neovascularization over 18 years old visual acuity ranger for count finger to 0,5 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: ocular infection in progress retinal detachment or severe retinopathy glaucoma severe immunodepression diabetic decompensation high systemic thrombosis risk
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: to evaluate efficacy and safety of topical bevacizumab in the therapy of corneal neovascularization. to restore corneal transparency and avasculariry and to improve visual acuity;Secondary Objective: and to improve visual acuity;Primary end point(s): to reduce corneal neovascularization | — |
Countries
Italy
Outcome results
None listed